pharma · EBV-induced Lymphomas · Coronary Artery Disease
Evidence Based Cataract
Evidence Based Cataract Study Group
Evidence Based Cataract is a pharma organization headquartered in THOUSAND OAKS, CA, CN. Primary therapeutic focus areas include EBV-induced Lymphomas, Coronary Artery Disease, Primary Progressive Multiple Sclerosis, Lup
THOUSAND OAKS, CA, CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- THOUSAND OAKS, CA, CN
- Programs
- 10
- Drugs
- 8
- Patents
- 10
ATA3219
Phase 1 · small molecule · Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ATA3219 for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma is a Phase 1 program (small_molecule) at Evidence Based Cataract Study Group with 1 ClinicalTrials.gov record(s).
Internal code ATA3219-NHL-103
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Evidence Based Cataract Study Group
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Status
- terminated
- Trials
- 1